Erzhi pills reverse PD-L1-mediated immunosuppression in melanoma microenvironment
Background: Cancer immunotherapies aimed at activating immune system, especially by blocking immune checkpoints, have become a successful modality for treating patients with advanced cancers. However, its clinical practice is frequently conceded by high outcomes, low initial response rates and sever...
Main Authors: | Zhirui Fang, Yuejin Xue, Yuze Leng, Lusha Zhang, Xiuyun Ren, Ning Yang, Jing Chen, Lu Chen, Hong Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-02-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844024010193 |
Similar Items
-
Data analysis of PD-1 antibody in the treatment of melanoma patients
by: Ting Li, et al.
Published: (2020-06-01) -
Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
by: Katarzyna Tomela, et al.
Published: (2023-03-01) -
Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
by: Ronen Stoff, et al.
Published: (2023-05-01) -
Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity
by: Kathleen M. Kokolus, et al.
Published: (2019-02-01) -
Survival Benefits of Anti-PD-1 Therapy in Combination With Radiotherapy in Chinese Melanoma Patients With Brain Metastasis
by: Shuang Wu, et al.
Published: (2021-03-01)